We show that the protective effect of SGLT-2 inhibitors is maintained as kidney function declines and that, due to the high baseline risk in patients with CKD, the absolute risk reduction with this treatment is greater in these patients. This evidence concerns the gene SLC5A2 and chronic kidney disease.